SCHEMBL1811086

SCHEMBL1811086

CN(C)[C@@H]1CCN(C(=O)c2ccc(-n3c(-c4ccccc4)nc4ccccc43)cc2)C1

nearest known ligand 0.72

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 18/20 0.72
KCNH2 Q12809 2/20 0.49
ATR Q13535 1/20 0.49
ESR1 P03372 1/20 0.49
ESR2 Q92731 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1810394 1.00 HRH3 (0.72) HRH3KCNH2ATRESR1ESR2
SCHEMBL1814327 1.00 HRH3 (0.72) HRH3KCNH2ATRESR1ESR2
SCHEMBL1812862 0.89 HRH3 (0.71) HRH3KCNH2
SCHEMBL2878779 0.84 HRH3 (1.00) HRH3KCNH2
SCHEMBL2881658 0.84 HRH3 (1.00) HRH3KCNH2
SCHEMBL2885885 0.84 HRH3 (1.00) HRH3KCNH2
SCHEMBL1813697 0.82 HRH3 (0.79) HRH3ESR1ESR2
SCHEMBL1814566 0.81 HRH3 (0.55) HRH3ATR
SCHEMBL1812972 0.80 HRH3 (0.56) HRH3KCNH2ATR
SCHEMBL1809344 0.78 HRH3 (0.56) HRH3ATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935719-B2 N-substituted-azacyclylamines as histamine-3 antagonists WYETH LLC (US) 2011-05-03 US disclosed
EP-2074088-A2 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS Wyeth (US) 2009-07-01 EP disclosed
US-20080119458-A1 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2008-05-22 US disclosed
WO-2008045371-A2 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS WYETH (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119458-A1 N-SUBSTITUTED-AZACYCLYLAMINES AS HISTAMINE-3 ANTAGONISTS HNMT, HRH4, HRH3 HRH3 3/4885KCNH2 603/4885ATR 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.